A Phase IB, Multicenter, Open-label Dose Escalation Study of the PI3K Inhibitor BYL719 in Combination With the HSP90 Inhibitor AUY922 in Patients With Advanced or Metastatic Gastric Cancer Carrying a Molecular Alteration of PIK3CA or an Amplification of HER2
Phase of Trial: Phase I
Latest Information Update: 16 Feb 2017
At a glance
- Drugs Alpelisib (Primary) ; Luminespib (Primary)
- Indications Gastric cancer; Oesophageal cancer
- Focus Adverse reactions
- Sponsors Novartis
- 10 Jun 2017 Biomarkers information updated
- 25 Feb 2014 Planned End Date changed from 1 Jul 2014 to 1 May 2014, as per ClinicalTrials.gov record.
- 09 Apr 2013 New source identified and integrated (M.D. Anderson Cancer Center: 2012-0872).